- This event has passed.
Sector Deep Dive: BioPharma
June 28 @ 6:00 pm - 7:00 pm
As the next part of BYHP’s Health Sector Deep Dive series, BYHP is hosting a comprehensive discussion on all things BioPharma, featuring speakers Rachele Ryan, Dan Adams and Lori Dinh. Topics of discussion will include research & development, policy, advice for breaking into a career in BioPharma, and more.
Rachele Ryan is the Director of Partnerships at LabCentral, a Massachusetts non-profit company, founded in 2013 as a launchpad for high-potential life sciences and biotech startups. In this role she is responsible for business development strategy, resident growth and development, and leading entrepreneurship programming for LabCentral’s newest initiative, LabCentral Ignite.
Rachele has over 7 years of experience connecting startups to the Boston/Cambridge innovation ecosystem. Prior to joining LabCentral, Rachele led the MassCONNECT mentoring program at MassBio, the Massachusetts biopharma industry association. In that role, she matched life sciences entrepreneurs and founders with seasoned life science professionals to catalyze and commercialize innovation. Previously, as a part of the International Business Development team at the Consulate General of Canada in Boston, she assisted Canadian companies with their expansion efforts into New England and supported fast-growing startups participating in the Canadian Technology Accelerator in Boston (CTA@Boston).
Rachele holds a BA from College of the Holy Cross and an MA from Middlebury College.
Dan Adams earned his PhD at the University of Colorado where he used a multidisciplinary approach to interrogate the molecular mechanisms of Aβ42-mediated synaptic dysfunction and neurotoxicity in Alzheimer’s disease. He then began his career in drug discovery, joining the founding team of an early stage start-up as the first employee with primary responsibility for all scientific R&D efforts. Dan led the company through target validation, screening, hit-to-lead and proof-of-concept rodent pharmacology work to deliver commercially promising therapeutic lead compounds in three disease areas. Next, he joined a drug safety innovation unit at Amgen where he established and validated multiple novel human-based in vitro predictive safety models and led investigative toxicology studies to support progression of discovery-stage assets.
Dan is now at Skyhawk Therapeutics where he leads a team building and implementing stem cell-derived models of human neurodegenerative diseases to support discovery biology efforts across the neuroscience portfolio.
*speaker bio to come*